NEW
YORK, July 6, 2023 /PRNewswire/ -- The Gross Law
Firm issues the following notice to shareholders of Regeneron
Pharmaceuticals, Inc.:
The investigation focuses on whether the Company issued false
and/or misleading statements and/or failed to disclose information
pertinent to investors. Regeneron received a response letter from
the FDA on June 27, 2023, declining
to approve its application for an 8mg dose of aflibercept, marketed
in the U.S. as Eylea. The Company claims that the denial is due to
an ongoing review of findings at a third-party filler. Based on
this news, shares of Regeneron dropped more than 9% on the same
day.
Due to the forgoing, The Gross Law Firm is investigating
potential securities fraud claims on behalf of certain
Regeneron investors. If you incurred a loss on your REGN
investment, please contact us using the link below to discuss your
rights.
https://securitiesclasslaw.com/securities/regeneron-loss-submission-form/?id=41698&from=4
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/investigation-alert-the-gross-law-firm-notifies-shareholders-of-regeneron-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit--nasdaq-regn-301870523.html
SOURCE The Gross Law Firm